Published in Infect Immun on October 01, 1983
Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae type b. Infect Immun (1985) 2.99
Characterization of antigens from nontypable Haemophilus influenzae recognized by human bactericidal antibodies. Role of Haemophilus outer membrane proteins. J Clin Invest (1985) 2.09
Conservation of epitopes in the oligosaccharide portion of the lipooligosaccharide of Haemophilus influenzae type b. Infect Immun (1987) 2.06
Antigenic diversity of lipooligosaccharides of nontypable Haemophilus influenzae. Infect Immun (1987) 1.87
Coprecipitation of lipopolysaccharide and the 39,000-molecular-weight major outer membrane protein of Haemophilus influenzae type b by lipopolysaccharide-directed monoclonal antibody. Infect Immun (1985) 1.84
Protection of infant rats from Haemophilus influenzae type b infection by antiserum to purified outer membrane protein a. Infect Immun (1987) 1.75
Protection by serum antibodies in experimental nontypable Haemophilus influenzae otitis media. Infect Immun (1986) 1.66
Composition and antigenic activity of the oligosaccharide moiety of Haemophilus influenzae type b lipooligosaccharide. Infect Immun (1985) 1.62
Comparison of sodium dodecyl sulfate-polyacrylamide gel electrophoresis profiles and antigenic relatedness among outer membrane proteins of 49 Brucella abortus strains. Infect Immun (1984) 1.40
Variability of outer membrane protein P1 and its evaluation as a vaccine candidate against experimental otitis media due to nontypeable Haemophilus influenzae: an unambiguous, multifaceted approach. Infect Immun (2000) 1.36
Cloning of the gene encoding the major outer membrane protein of Haemophilus influenzae type b. Infect Immun (1988) 1.27
Immune enhancement of pulmonary clearance of nontypable Haemophilus influenzae. Infect Immun (1988) 1.23
Antigenic diversity and gene polymorphisms in Haemophilus influenzae. Infect Immun (1998) 1.19
Primary structure of the porin protein of Haemophilus influenzae type b determined by nucleotide sequence analysis. Infect Immun (1989) 1.19
Serum opsonic activity after immunization of adults with Haemophilus influenzae type b-diphtheria toxoid conjugate vaccine. Infect Immun (1985) 1.09
Lipopolysaccharide gel profiles of Haemophilus influenzae type b are not stable epidemiologic markers. J Clin Microbiol (1986) 1.07
Isolation and characterization of a mutant of Haemophilus influenzae type b deficient in outer membrane protein P1. Infect Immun (1989) 1.03
Cross-reactivity of surface-exposed epitopes of outer membrane antigens of Haemophilus influenzae type b. Infect Immun (1987) 0.97
Outer membrane proteins of nontypable Haemophilus influenzae and reactivity of paired sera from infected patients with their homologous isolates. Infect Immun (1985) 0.94
Serum antibody response to capsular polysaccharide, outer membrane, and lipooligosaccharide in children with invasive Haemophilus influenzae type b infections. J Clin Microbiol (1987) 0.87
Comparison of methods for serotyping isolates of Haemophilus influenzae. J Clin Microbiol (1985) 0.86
Antibodies to lipooligosaccharide of a Brazilian purpuric fever isolate of Haemophilus influenzae biogroup aegyptius lack bactericidal and protective activity. Infect Immun (1992) 0.83
Antibody to the outer membrane proteins is the dominant opsonic antibody in normal human serum against H. influenzae type b. Immunology (1989) 0.82
Complement component 3 binding to Haemophilus influenzae type b in the presence of anticapsular and anti-outer membrane antibodies. Infect Immun (1992) 0.82
Experimental meningitis in the rat: Haemophilus influenzae. Infection (1984) 0.80
Antibodies to Haemophilus influenzae type b outer membrane proteins in children with epiglottitis or meningitis and in healthy controls. Infect Immun (1993) 0.80
Outer membrane protein binding sites of complement component 3 during opsonization of Haemophilus influenzae. Infect Immun (1993) 0.79
Antibodies to outer membrane proteins but not to lipopolysaccharide inhibit pulmonary proliferation of Pasteurella multocida in mice. Infect Immun (1991) 0.79
Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol (1975) 47.77
Electrophoretic resolution of the "major outer membrane protein" of Escherichia coli K12 into four bands. FEBS Lett (1975) 26.78
Human serum activities against Hemophilus influenzae, type b. J Clin Invest (1972) 7.85
Subtyping isolates of Haemophilus influenzae type b by outer-membrane protein profiles. J Infect Dis (1981) 6.34
A new spectrophotometric assay for protein in cell extracts. Anal Biochem (1977) 6.30
Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications. Infect Immun (1980) 5.68
Production of Haemophilus influenzae b meningitis in infant rats by intraperitoneal inoculation. Infect Immun (1973) 4.80
Identification of immunogenic outer membrane proteins of Haemophilus influenzae type b in the infant rat model system. Infect Immun (1981) 3.37
Surface-exposed protein antigens of the gonococcal outer membrane. Infect Immun (1981) 3.28
Antibody response of infants to cell surface-exposed outer membrane proteins of Haemophilus influenzae type b after systemic Haemophilus disease. Infect Immun (1982) 3.18
Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b: a field trial in Finland. J Infect Dis (1977) 2.79
Immunoprotection of rats against Haemophilus influenzae type B disease mediated by monoclonal antibody against a haemophilus outer-membrane protein. Lancet (1982) 2.53
Experimental Haemophilus influenzae type b meningitis: immunological investigation of the infant rat model. Infect Immun (1978) 2.46
Phenotypic and genetic variation in the susceptibility of Haemophilus influenzae type b to antibodies to somatic antigens. J Clin Invest (1980) 2.42
Detection of antibody-accessible proteins on the cell surface of Haemophilus influenzae type b. Infect Immun (1981) 2.41
Characterization of lipopolysaccharide of Haemophilus influenzae. J Infect Dis (1978) 2.18
The role of encapsulation and host age in the clearance of Haemophilus influenzae bacteremia. J Infect Dis (1977) 2.01
The paradox of Hemophilus infuenzae type B bacteremia in the presence of serum bactericidal activity. J Clin Invest (1976) 1.94
Human antibody responses to lipopolysaccharide after meningitis due to Haemophilus influenzae type b. J Infect Dis (1982) 1.87
Role of immunity in the clearance of bacteremia due to Haemophilus influenzae. J Infect Dis (1978) 1.65
A radioactive antigen-binding assay for the measurement of antibody to Haemophilus influenzae type b capsular polysaccharide. J Immunol Methods (1981) 1.65
Induction of immunity against lethal Haemophilus influenzae type b infection by Escherichia coli core lipopolysaccharide. J Clin Invest (1982) 1.59
The infant rat as a model of bacterial meningitis. J Infect Dis (1977) 1.44
Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J Infect Dis (1980) 1.26
Reassessment of the role of bactericidal antibody in Hemophilus influenzae infection. Am J Med Sci (1971) 1.19
Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976). J Infect Dis (1977) 1.08
Immunoadsorbents. Methods Enzymol (1974) 1.02
Immunity to Haemophilus influenzae type B: the nature of the bactericidal antibody in human blood. J Med Microbiol (1971) 1.00
Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science (2000) 7.41
Subtyping isolates of Haemophilus influenzae type b by outer-membrane protein profiles. J Infect Dis (1981) 6.34
Genetic relationships of serologically nontypable and serotype b strains of Haemophilus influenzae. Infect Immun (1986) 5.92
A population genetic framework for the study of invasive diseases caused by serotype b strains of Haemophilus influenzae. Proc Natl Acad Sci U S A (1985) 4.48
Global genetic structure and molecular epidemiology of encapsulated Haemophilus influenzae. Rev Infect Dis (1990) 4.06
Outer membrane protein and biotype analysis of pathogenic nontypable Haemophilus influenzae. Infect Immun (1982) 3.78
Purification and comparison of outer membrane protein P2 from Haemophilus influenzae type b isolates. J Clin Invest (1983) 3.33
High-molecular-weight proteins of nontypable Haemophilus influenzae mediate attachment to human epithelial cells. Proc Natl Acad Sci U S A (1993) 3.18
Purification and partial characterization of outer membrane proteins P5 and P6 from Haemophilus influenzae type b. Infect Immun (1985) 2.99
A diffusible cytotoxin of Haemophilus ducreyi. Proc Natl Acad Sci U S A (1997) 2.89
Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan. Lancet (1991) 2.63
Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA (1998) 2.50
Experimental Haemophilus influenzae type b meningitis: immunological investigation of the infant rat model. Infect Immun (1978) 2.46
Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA (1992) 2.40
From the Infectious Diseases Society of America. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis (1990) 2.39
Prospects for prevention of Haemophilus influenzae type b disease by immunization. J Infect Dis (1986) 2.31
1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. Clin Infect Dis (1997) 2.14
Comparison of outer-membrane protein subtypes and biotypes of isolates of Haemophilus influenzae type b. J Infect Dis (1981) 2.07
Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA (1993) 2.05
Outer-membrane protein subtypes of Haemophilus influenzae type b and spread of disease in day-care centers. J Infect Dis (1981) 2.03
Prevalence and distribution of the hmw and hia genes and the HMW and Hia adhesins among genetically diverse strains of nontypeable Haemophilus influenzae. Infect Immun (1998) 1.94
Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. J Infect Dis (1984) 1.89
Human antibody responses to lipopolysaccharide after meningitis due to Haemophilus influenzae type b. J Infect Dis (1982) 1.87
Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Infect Dis (1997) 1.86
Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J Infect Dis (1985) 1.84
Characterization of the genetic locus encoding Haemophilus influenzae type b surface fibrils. J Bacteriol (1996) 1.81
Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun (1999) 1.76
Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr (1993) 1.69
Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine (2006) 1.67
Protection by serum antibodies in experimental nontypable Haemophilus influenzae otitis media. Infect Immun (1986) 1.66
Pneumolysin, a protein toxin of Streptococcus pneumoniae, induces nitric oxide production from macrophages. Infect Immun (1999) 1.60
Variation in expression of the Haemophilus influenzae HMW adhesins: a prokaryotic system reminiscent of eukaryotes. Proc Natl Acad Sci U S A (1999) 1.60
Cloning and characterization of the genes encoding the hemolysin of Haemophilus ducreyi. Mol Microbiol (1995) 1.59
Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol (2001) 1.57
An isogenic haemolysin-deficient mutant of Haemophilus ducreyi lacks the ability to produce cytopathic effects on human foreskin fibroblasts. Mol Microbiol (1996) 1.55
Spread of Haemophilus influenzae type b: recent epidemiologic and therapeutic considerations. J Pediatr (1980) 1.55
Expression of peptidoglycan-associated lipoprotein is required for virulence in the human model of Haemophilus ducreyi infection. Infect Immun (2000) 1.53
Molecular conservation of the P6 outer membrane protein among strains of Haemophilus influenzae: analysis of antigenic determinants, gene sequences, and restriction fragment length polymorphisms. Infect Immun (1991) 1.49
Second episodes of Haemophilus influenzae type b disease following rifampin prophylaxis of the index patients. Pediatr Infect Dis J (1987) 1.47
Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis (2009) 1.47
Functional differences in idiotypically defined IgG1 anti-polysaccharide antibodies elicited by vaccination with Haemophilus influenzae type B polysaccharide-protein conjugates. J Immunol (1995) 1.47
Outer membrane protein profiles of Haemophilus pleuropneumoniae. Infect Immun (1986) 1.46
Antibody responses to Haemophilus influenzae type b polysaccharide vaccine in relation to Km(1) and G2m(23) immunoglobulin allotypes. J Infect Dis (1986) 1.43
Variability in the functional activity of vaccine-induced antibody to Haemophilus influenzae type b. Pediatr Res (1990) 1.43
Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein. Lancet (1986) 1.42
Complement-mediated bactericidal activity of human antibodies to poly alpha 2-->8 N-acetylneuraminic acid, the capsular polysaccharide of Neisseria meningitidis serogroup B. J Infect Dis (1995) 1.41
Characterization of a transposon Tn916-generated mutant of Haemophilus ducreyi 35000 defective in lipooligosaccharide biosynthesis. J Bacteriol (1997) 1.41
Immunogenicity of Haemophilus influenzae type b polysaccharide--diphtheria toxoid conjugate vaccine in adults. J Pediatr (1984) 1.41
Subclass distribution of human antibodies to Haemophilus influenzae type b capsular polysaccharide. J Immunol (1987) 1.38
Haemophilus influenzae type B disease in a day care center: eradication of carrier state by rifampin. Pediatrics (1979) 1.37
Aspergillosis in children with cancer: A 34-year experience. Clin Infect Dis (1999) 1.37
Do children with recurrent Haemophilus influenzae otitis media become infected with a new organism or reacquire the original strain? J Pediatr (1984) 1.36
Hemophilus influenzae type B disease in children vaccinated with type B polysaccharide vaccine. N Engl J Med (1986) 1.36
Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer (2001) 1.36
Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b. J Infect Dis (1990) 1.35
Comparison of outer membrane protein subtypes of Haemophilus influenzae type b isolates from healthy children in the general population and from diseased patients. J Clin Microbiol (1983) 1.34
Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis (1991) 1.33
Identification of a hemolytic activity elaborated by Haemophilus ducreyi. Infect Immun (1994) 1.32
Effect of normal and immune sera on Haemophilus ducreyi 35000HP and its isogenic MOMP and LOS mutants. Microb Pathog (1999) 1.31
Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. J Pediatr (1988) 1.30
Response to immunization with Haemophilus influenzae type b polysaccharide-pertussis vaccine and risk of Haemophilus meningitis in children with the Km(1) immunoglobulin allotype. J Clin Invest (1984) 1.28
Failure of monoclonal antibodies to core glycolipid to bind intact smooth strains of Escherichia coli. J Infect Dis (1985) 1.28
Haemophilus influenzae infections in Fresno County, California: a prospective study of the effects of age, race, and contact with a case on incidence of disease. J Infect Dis (1980) 1.26
Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis. Infect Immun (1998) 1.26
Biosynthesis of lipid A. Enzymatic incorporation of 3-deoxy-D-mannooctulosonate into a precursor of lipid A in Salmonella typhimurium. J Biol Chem (1978) 1.25
Infectious diseases and child day care. Pediatrics (1984) 1.25
An idiotypic marker associated with a germ-line encoded kappa light chain variable region that predominates the vaccine-induced human antibody response to the Haemophilus influenzae b polysaccharide. J Clin Invest (1991) 1.24
Evaluation of an isogenic hemolysin-deficient mutant in the human model of Haemophilus ducreyi infection. J Infect Dis (1998) 1.24
In situ management of confirmed central venous catheter-related bacteremia. Pediatr Infect Dis J (1987) 1.24
Antibody-dependent alternative pathway killing of Haemophilus influenzae type b. Infect Immun (1984) 1.24
Polymyxin B prevents lipopolysaccharide-induced release of tumor necrosis factor-alpha from alveolar macrophages. J Infect Dis (1989) 1.22
Functional activity of anti-Neisserial surface protein A monoclonal antibodies against strains of Neisseria meningitidis serogroup B. Infect Immun (2001) 1.21
Facile construction of mutations in Haemophilus ducreyi using lacZ as a counter-selectable marker. FEMS Microbiol Lett (1998) 1.20
Outer membrane protein subtypes and biotypes of Haemophilus influenzae type b: relation between strains isolated in 1934-1954 and 1977-1980. J Infect Dis (1983) 1.20
Expression of cytolethal distending toxin and hemolysin is not required for pustule formation by Haemophilus ducreyi in human volunteers. Infect Immun (2001) 1.19
Comparison of rifampin and ampicillin in day care center contacts of Haemophilus influenzae type b disease. Pediatrics (1980) 1.17
Bacillus cereus bacteremia and meningitis in immunocompromised children. Clin Infect Dis (2001) 1.16